A changing treatment landscape for multiple sclerosis: challenges and opportunities

被引：47
作者：
Piehl, F. [1 ]
机构：
[1] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
来源：
JOURNAL OF INTERNAL MEDICINE | 2014年 / 275卷 / 04期
关键词：
multiple sclerosis; immunomodulatory therapy; biological therapies; randomized controlled trial; PLACEBO-CONTROLLED TRIAL; FUMARIC-ACID ESTERS; MEMORY T-CELLS; DOUBLE-BLIND; NATALIZUMAB TREATMENT; CONTROLLED PHASE-3; INTERFERON-BETA; DISEASE-ACTIVITY; BREAKTHROUGH DISEASE; GLATIRAMER ACETATE;
D O I：
10.1111/joim.12204
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Multiple sclerosis (MS) is primarily an autoimmune disease of the central nervous system, but also encompasses prominent neurodegenerative aspects. A significant proportion of MS patients will develop neurological disability over time and up until recently treatment options have been limited. However, MS treatment is now at a stage of rapid progress, with several new drugs that have reached the market or will be launched in the near future. This provides new opportunities for individualized treatment, but also creates new challenges regarding monitoring of disease activity, long-term safety issues and efficacy, not least in patients with progressive disease.
引用
收藏
页码：364 / 381
页数：18
相关论文
共 89 条
  • [1] Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis
    Axelsson, Markus
    Malmestrom, Clas
    Gunnarsson, Martin
    Zetterberg, Henrik
    Sundstrom, Peter
    Lycke, Jan
    Svenningsson, Anders
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (01) : 43 - 50
  • [2] Interferon-β treatment for multiple sclerosis
    Bermel, Robert A.
    Rudick, Richard A.
    [J]. NEUROTHERAPEUTICS, 2007, 4 (04) : 633 - 646
  • [3] Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis
    Bielekova, B
    Catalfamo, M
    Reichert-Scrivner, S
    Packer, A
    Cerna, M
    Waldmann, TA
    McFarland, H
    Henkart, PA
    Martin, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) : 5941 - 5946
  • [4] Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β
    Bielekova, B
    Richert, N
    Howard, T
    Blevins, G
    Markovic-Plese, S
    McCartin, J
    Würfel, J
    Ohayon, J
    Waidmann, TA
    McFarland, HF
    Martin, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (23) : 8705 - 8708
  • [5] Effect of Natalizumab on Circulating CD4+ T-Cells in Multiple Sclerosis
    Bornsen, Lars
    Christensen, Jeppe Romme
    Ratzer, Rikke
    Oturai, Annette Bang
    Sorensen, Per Soelberg
    Sondergaard, Helle Bach
    Sellebjerg, Finn
    [J]. PLOS ONE, 2012, 7 (11):
  • [6] Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
    Brueck, Wolfgang
    Pfoertner, Ramona
    Trinh Pham
    Zhang, Jingya
    Hayardeny, Liat
    Piryatinsky, Victor
    Hanisch, Uwe-Karsten
    Regen, Tommy
    van Rossum, Denise
    Brakelmann, Lars
    Hagemeier, Karin
    Kuhlmann, Tanja
    Stadelmann, Christine
    John, Gareth R.
    Kramann, Nadine
    Wegner, Christiane
    [J]. ACTA NEUROPATHOLOGICA, 2012, 124 (03) : 411 - 424
  • [7] Burt RK, 2009, LANCET NEUROL, V8, P244, DOI 10.1016/S1474-4422(09)70017-1
  • [8] Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
    Cohen, Jeffrey A.
    Coles, Alasdair J.
    Arnold, Douglas L.
    Confavreux, Christian
    Fox, Edward J.
    Hartung, Hans-Peter
    Havrdova, Eva
    Selmaj, Krzysztof W.
    Weiner, Howard L.
    Fisher, Elizabeth
    Brinar, Vesna V.
    Giovannoni, Gavin
    Stojanovic, Miroslav
    Ertik, Bella I.
    Lake, Stephen L.
    Margolin, David H.
    Panzara, Michael A.
    Compston, D. Alastair S.
    [J]. LANCET, 2012, 380 (9856) : 1819 - 1828
  • [9] Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects
    Cohen, Jeffrey A.
    Reingold, Stephen C.
    Polman, Chris H.
    Wolinsky, Jerry S.
    [J]. LANCET NEUROLOGY, 2012, 11 (05) : 467 - 476
  • [10] Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
    Cohen, Jeffrey A.
    Barkhof, Frederik
    Comi, Giancarlo
    Hartung, Hans-Peter
    Khatri, Bhupendra O.
    Montalban, Xavier
    Pelletier, Jean
    Capra, Ruggero
    Gallo, Paolo
    Izquierdo, Guillermo
    Tiel-Wilck, Klaus
    de Vera, Ana
    Jin, James
    Stites, Tracy
    Wu, Stacy
    Aradhye, Shreeram
    Kappos, Ludwig
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (05) : 402 - 415
123456789